Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Optical Coherence Tomography Shown to Predict Tumor Margins Effectively

By Medimaging International staff writers
Posted on 28 Jan 2013
Print article
Image: The VivoSight optical coherence tomography (OCT) scanner (Photo courtesy of Michelson Diagnostics).
Image: The VivoSight optical coherence tomography (OCT) scanner (Photo courtesy of Michelson Diagnostics).
A precise determination of tumor margins is vital for the effective treatment of skin cancer patients. This is particularly true for patients undergoing Mohs micrographic surgery, where complete tumor removal may require repeated invasive procedures.

Recent studies conducted in two US Healthcare facilities used the VivoSight optical coherence tomography (OCT) scanner, manufactured by Michelson Diagnostics, Ltd. (South London, UK), to prospectively improve clinically estimated tumor margins prior to Mohs micrographic surgery.

The first, a 52-patient study, conducted by Prof. Dan Seigel, from the department of dermatology, State University of New York Downstate Medical Center (Brooklyn, NY, USA), concluded that “OCT assessment has the potential to reduce the excised area without compromising the integrity of tumor-free borders.” The study’s findings were published January 2013 in the journal Dermatologic Surgery.

Another case study of a patient with very ill defined margins concluded that, “High-resolution imaging with a multibeam OCT device can accurately predict tumor margins of a BCC prior to Mohs micrographic surgery […] with any tumor, particularly ill-defined ones, the use of OCT could potentially reduce the number of stages required to clear the tumor leading to shorter operative times and reduction of cost.”

The findings were published December 2012 in the journal Case Reports in Dermatology by researchers from the Permanente Medical Group (Elk Grove, CA, USA) and SkinCare Physicians (Chestnut Hill, MA, USA).

Dr. Gertraud Kraehn-Senftleben, a dermatologists from Blaubeuren, Germany, and a member of the German Onkoderm Network, and one of the first clinicians to use the VivoSight OCT scanner in routine clinical practice, commented, “These studies reflect the day to day experience in our clinic. We routinely scan tumor margins prior to micrographic surgery and our experience of more than 150 patients is that it reduces the amount of repeat surgery required. This is a great benefit for both the patient and the dermatologist.”

Related Links:
Michelson Diagnostics
State University of New York Downstate Medical Center
SkinCare Physicians



Print article
Radcal

Channels

Nuclear medicine

view channel
Image: The newly approved PET imaging agent Fluciclovine (18F) anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC) is a synthetic amino acid (Photo courtesy of Blue Earth Diagnostics).

New PET Imaging Agent for Recurrent Prostate Cancer Approved by US FDA

The US Food and Drug Administration (FDA) has approved the first PET imaging molecular imaging agent for use in patients who have suspected recurrent prostate cancer. The agent is indicated for use... Read more

Imaging IT

view channel
Image: New workflow options are available for the Compass Routing and Workflow Manager (Photo courtesy of Laurel Bridge Software).

Enterprise Workflow Solutions Provider Announces New Options

A software company that provides enterprise medical imaging workflow solutions has announced that it has added new workflow features for the company’s routing and workflow management system.... Read more

Industry News

view channel

Nuclear Medicine Market Exhibits Slow Growth

The slow growth of the global nuclear medicine market is driven by lower revenues from technetium-99m-related products and unfavorable USD exchange rates against major currencies. These are the latest findings of Medraysintell (Louvain-la-Neuve, Belgium), a provider of strategic intelligence for radiation healthcare.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.